The Fifth U.S. Circuit Court of Appeals on Friday barred the mailing of the abortion pill mifepristone across the United States, reversing FDA rules that had allowed women to obtain the drug by mail and through pharmacies without an in-person visit. The ruling reinstates earlier safety protocols requiring face-to-face dispensing at clinics, a decision the court itself acknowledged would, "as a practical matter, have a nationwide effect."
The order lands at the center of the most consequential legal fight over abortion access since the Supreme Court overturned Roe v. Wade in 2022. Mifepristone is one of two drugs commonly used in medication abortions, which account for a majority of all abortions performed in the United States, according to research from the Guttmacher Institute. Roughly one in four abortions nationally are now prescribed via telehealth, a channel the ruling effectively shuts down.
The case is widely expected to reach the Supreme Court. Danco Laboratories, the drug's distributor, has already filed a request for a temporary administrative stay, asking for one week to seek emergency relief from the high court.
A unanimous three-judge panel found that the FDA acted unreasonably when it loosened mifepristone's safety requirements. The judges zeroed in on a specific regulatory maneuver: the agency had eliminated the requirement to report the drug's adverse events, then pointed to the resulting lack of data to justify expanding access further.
The court called that reasoning "unreasonable", a polite judicial word for a circular argument that would embarrass a first-year law student.
Judge Stuart Kyle Duncan, writing for the panel, framed Louisiana's position in stark terms. The state argued that the FDA's mail-order regime caused "irreparable harm every day" it remained in place, because expanded access was designed to "reach into jurisdictions like Louisiana" despite that state's abortion restrictions.
As Duncan wrote in the opinion:
"By ending the in-person dispensing requirement, FDA opened the door for mifepristone to be remotely prescribed to Louisiana women."
The court went further, declaring that "every abortion facilitated by FDA's action cancels Louisiana's ban" and citing Louisiana law's recognition that "every unborn child is [a] human being... from the moment of conception." The panel concluded: "Once lost, that sovereign prerogative of protecting unborn life cannot be regained."
The requirement that women see a medical professional before obtaining a mifepristone prescription was lifted during the COVID-19 pandemic under former President Joe Biden. What began as a pandemic-era exception hardened into permanent policy when the FDA in 2023 formally removed in-person dispensing rules, opening the door to online prescriptions and mail delivery nationwide.
For pro-life states, the effect was immediate and corrosive. Mail-order pills flowed across state lines, bypassing restrictions that voters and legislators in those states had enacted through the democratic process. Louisiana's Attorney General Liz Murrill argued the policy was not neutral, it was designed to undercut state-level bans by making the drug available to anyone with an internet connection, regardless of where she lived.
The broader legal landscape around abortion continues to shift rapidly. In Arizona, for instance, a judge recently struck down three abortion laws, prompting Republican leaders to vow an appeal, another front in the ongoing contest between state legislatures and the judiciary over who sets the boundaries of abortion policy.
A federal judge had allowed mifepristone to remain available by mail on a temporary basis last month while legal challenges and federal review efforts continued. The Department of Health and Human Services and the FDA remain tasked with examining safety data, adverse events, and the regulatory framework surrounding the drug. Friday's ruling overrides that temporary arrangement.
Pro-life leaders greeted the decision as a long-overdue correction. Students for Life President Kristan Hawkins said the ruling validated years of advocacy:
"This is a win we've been waiting for, and we pray it holds. We can't remain the United States of America if abortion-loving states allow criminal enterprises to be set up, breaking the laws of their pro-life neighbors."
Family Research Council President Tony Perkins, a former Louisiana state representative, called the ruling "great news for the unborn" and predicted the issue "should be before the U.S. Supreme Court soon."
Carol Tobias, president of the National Right to Life Committee, framed the decision as a patient-safety issue. "Women deserve better than an abortion-by-mail system that prioritizes ideology over safety," Tobias said.
On the other side, New York Attorney General Letitia James called mifepristone "safe, effective and essential" and labeled the ruling "yet another cruel attack on abortion access." James added: "Restrictions on abortion care are restrictions on life-saving health care."
The ACLU's Julia Kaye warned the ruling would ripple far beyond states with existing bans. "This is going to affect patients' access to abortion and miscarriage care in every state in the nation," Kaye said. Nancy Northup of the Center for Reproductive Rights was more pointed, claiming, "This isn't about science, it's about making abortion as difficult, expensive, and unreachable as possible."
The case now heads toward the same court that overturned Roe v. Wade three years ago. Danco Laboratories has already signaled it will seek emergency relief from the justices, filing a request for a one-week administrative stay to prepare its appeal.
The Supreme Court has been active on a range of high-stakes legal disputes this term, from qualified immunity and death-row DNA cases to First Amendment challenges. Adding mifepristone to the docket would force the justices to confront the intersection of federal regulatory power, state sovereignty, and abortion access head-on.
Judge David C. Joseph, who handled an earlier phase of the litigation, had cautioned against "government by lawsuit" and emphasized that the FDA's ongoing safety review, not litigation, should determine long-term policy. But the Fifth Circuit panel evidently concluded that the FDA's review process was itself compromised by the agency's own data gaps.
That finding matters. If the Supreme Court agrees that the FDA stripped away safety reporting requirements and then used the absence of adverse-event data to justify loosening access, the regulatory framework around mifepristone could face a fundamental reset. The question is not just whether women can receive the drug by mail. It is whether a federal agency can engineer a data vacuum and then cite that vacuum as evidence of safety.
The conservative legal movement has long argued that post-Dobbs, abortion policy belongs to the states. This ruling reinforces that principle. As Justice Alito recently reflected on the late Justice Scalia's legacy, the broader question of how far the judiciary should go in policing regulatory overreach remains central to the conservative legal project.
For now, women seeking mifepristone must obtain it in person from a health clinic. The mail-order pipeline that became the dominant channel for medication abortions after Roe fell is, at least temporarily, closed.
The FDA and HHS still face their own review obligations. The agency's handling of that review, whether it addresses the data gaps the Fifth Circuit identified or doubles down on the same circular reasoning, will shape the legal battlefield before the Supreme Court.
Pro-life advocates see the ruling as vindication. Pro-choice groups see it as a crisis. Both sides agree on one thing: this fight is heading to the highest court in the land.
When a federal agency rigs its own data collection to produce the answer it wants, and a court finally calls the bluff, that is not an attack on health care. That is accountability.
